Dianthus Therapeutics, Inc. /DE/ (DNTH): who owns it and who trades it
As of Nov 16, 2026, DNTH insiders reported 70 open-market sales worth $75M and no purchases in the last 12 months, with 15% of the sale value made under pre-set 10b5-1 plans. The largest seller was Marino Garcia (CEO), with $28M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Dianthus Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns DNTH
265 funds and institutions reported DNTH shares worth $6.4B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 18.4%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 8.20M | 18.44% | $799M | +6% |
| BlackRock, Inc. | 4.12M | 9.27% | $402M | +30% |
| T. Rowe Price Investment Management, Inc. | 3.89M | 8.74% | $379M | +201% |
| Wellington Management Group LLP | 3.23M | 7.26% | $315M | +24% |
| Fairmount Funds Management LLC | 2.54M | 5.71% | $247M | No change |
| T. Rowe Price Associates | 2.51M | 5.66% | $245M | +119% |
| State Street Corp | 2.36M | 5.30% | $230M | +69% |
| Vanguard Capital Management LLC | 2.16M | 4.86% | $211M | +6% |
| Avidity Partners Management LP | 2.10M | 4.73% | $205M | -50% |
| Octagon Capital Advisors LP | 1.84M | 4.14% | $180M | -5% |
| TCG Crossover Management, LLC | 1.68M | 3.77% | $163M | No change |
| Fred Alger Management, LLC | 1.30M | 2.93% | $127M | +12% |
| Geode Capital Management, LLC | 1.26M | 2.83% | $123M | +37% |
| Venrock Adviser, LLC | 1.18M | 2.65% | $115M | No change |
| UBS Group AG | 1.14M | 2.56% | $111M | +46% |
| Deerfield Management Company, L.P. | 1.13M | 2.53% | $110M | +10% |
| Jennison Associates LLC | 1.02M | 2.30% | $99.6M | +111% |
| Polar Capital Holdings Plc | 1.02M | 2.29% | $99.3M | -5% |
| Citadel Advisors LLC | 974,911 | 2.19% | $95M | -39% |
| Franklin Resources Inc | 968,983 | 2.18% | $94.5M | +0% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, DNTH insiders reported $0 of open-market purchases and $75M of sales. 15% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Ryan Savitz | CFO | Sale plan | 17,724 | $90.56 | $1.6M | Form 4 |
| Nov 11, 2026 | Ryan Savitz | CFO | Sale plan | 3,044 | $90.03 | $274K | Form 4 |
| Nov 10, 2026 | Ryan Savitz | CFO | Sale plan | 2,561 | $90.14 | $231K | Form 4 |
| Nov 9, 2026 | Ryan Savitz | CFO | Sale plan | 300 | $85.16 | $25.5K | Form 4 |
| Nov 9, 2026 | Ryan Savitz | CFO | Sale plan | 700 | $86.70 | $60.7K | Form 4 |
| Nov 9, 2026 | Ryan Savitz | CFO | Sale plan | 1,736 | $88.84 | $154K | Form 4 |
| Nov 9, 2026 | Ryan Savitz | CFO | Sale plan | 37,517 | $90.12 | $3.4M | Form 4 |
| Nov 9, 2026 | Ryan Savitz | CFO | Sale plan | 58,396 | $90.90 | $5.3M | Form 4 |
| Nov 9, 2026 | Ryan Savitz | CFO | Sale plan | 2,064 | $91.59 | $189K | Form 4 |
| Sep 17, 2026 | Edward Carr | CHIEF ACCOUNTING OFFICER | Sale | 7,928 | $100.43 | $796K | Form 4 |
| Sep 17, 2026 | Edward Carr | CHIEF ACCOUNTING OFFICER | Sale | 6,771 | $101.37 | $686K | Form 4 |
| Sep 17, 2026 | Edward Carr | CHIEF ACCOUNTING OFFICER | Sale | 3,501 | $102.39 | $358K | Form 4 |
| Sep 17, 2026 | Edward Carr | CHIEF ACCOUNTING OFFICER | Sale | 700 | $104.39 | $73.1K | Form 4 |
| Sep 17, 2026 | Edward Carr | CHIEF ACCOUNTING OFFICER | Sale | 1,100 | $103.20 | $114K | Form 4 |
| Sep 1, 2026 | Simrat Randhawa | Vice president | Sale | 2,600 | $105.19 | $273K | Form 4 |
| Sep 1, 2026 | Simrat Randhawa | Vice president | Sale | 7,215 | $106.25 | $767K | Form 4 |
| Sep 1, 2026 | Simrat Randhawa | Vice president | Sale | 13,309 | $106.74 | $1.4M | Form 4 |
| Aug 19, 2026 | Simon Read | Director | Sale | 2,778 | $117.55 | $327K | Form 4 |
| Aug 10, 2026 | Anne McGeorge | Director | Sale | 1,000 | $110.64 | $111K | Form 4 |
| Aug 10, 2026 | Anne McGeorge | Director | Sale | 700 | $111.41 | $78K | Form 4 |
| Aug 10, 2026 | Anne McGeorge | Director | Sale | 1,800 | $109.30 | $197K | Form 4 |
| Aug 10, 2026 | Anne McGeorge | Director | Sale | 2,800 | $108.38 | $303K | Form 4 |
| Aug 10, 2026 | Anne McGeorge | Director | Sale | 1,450 | $107.58 | $156K | Form 4 |
| Aug 10, 2026 | Simon Read | Director | Sale | 70 | $107.11 | $7.5K | Form 4 |
| Aug 10, 2026 | Simon Read | Director | Sale | 737 | $108.17 | $79.7K | Form 4 |
| Aug 10, 2026 | Simon Read | Director | Sale | 831 | $108.95 | $90.5K | Form 4 |
| Aug 10, 2026 | Simon Read | Director | Sale | 272 | $109.96 | $29.9K | Form 4 |
| Aug 10, 2026 | Simon Read | Director | Sale | 397 | $111.77 | $44.4K | Form 4 |
| Aug 10, 2026 | Simon Read | Director | Sale | 470 | $111.05 | $52.2K | Form 4 |
| Aug 10, 2026 | Adam M Veness | Vice president | Sale | 16,167 | $110.38 | $1.8M | Form 4 |
| Aug 7, 2026 | Adam M Veness | Vice president | Sale | 616 | $111.18 | $68.5K | Form 4 |
| Aug 7, 2026 | Adam M Veness | Vice president | Sale | 3,217 | $110.61 | $356K | Form 4 |
| Aug 7, 2026 | Marino Garcia | CEO | Sale | 2,373 | $109.10 | $259K | Form 4 |
| Aug 7, 2026 | Marino Garcia | CEO | Sale | 2,536 | $110.02 | $279K | Form 4 |
| Aug 7, 2026 | Marino Garcia | CEO | Sale | 800 | $110.76 | $88.6K | Form 4 |
| Aug 7, 2026 | Marino Garcia | CEO | Sale | 104,091 | $107.96 | $11.2M | Form 4 |
| Aug 7, 2026 | Marino Garcia | CEO | Sale | 23,907 | $108.05 | $2.6M | Form 4 |
| Aug 7, 2026 | Marino Garcia | CEO | Sale | 10,384 | $107.49 | $1.1M | Form 4 |
| Aug 7, 2026 | Marino Garcia | CEO | Sale | 21,909 | $108.72 | $2.4M | Form 4 |
| Jul 9, 2026 | Ryan Savitz | CFO | Sale | 10,354 | $100.22 | $1M | Form 4 |
| Jul 9, 2026 | Ryan Savitz | CFO | Sale | 5,566 | $101.97 | $568K | Form 4 |
| Jul 9, 2026 | Ryan Savitz | CFO | Sale | 15,329 | $101.24 | $1.6M | Form 4 |
| Jun 17, 2026 | Adam M Veness | Vice president | Sale | 13,229 | $81.38 | $1.1M | Form 4 |
| Jun 17, 2026 | Adam M Veness | Vice president | Sale | 16,771 | $80.34 | $1.3M | Form 4 |
| Jun 1, 2026 | Simrat Randhawa | Vice president | Sale | 16,943 | $90.72 | $1.5M | Form 4 |
| Jun 1, 2026 | Simrat Randhawa | Vice president | Sale | 4,159 | $91.37 | $380K | Form 4 |
| Jun 1, 2026 | Simrat Randhawa | Vice president | Sale | 5,428 | $89.72 | $487K | Form 4 |
| May 8, 2026 | Paula Soteropoulos | Director | Sale | 599 | $85.47 | $51.2K | Form 4 |
| Apr 9, 2026 | Ryan Savitz | CFO | Sale | 8,224 | $89.84 | $739K | Form 4 |
| Mar 31, 2026 | Ryan Savitz | CFO | Sale | 21,825 | $78.86 | $1.7M | Form 4 |
| Mar 31, 2026 | Ryan Savitz | CFO | Sale | 1,485 | $80.25 | $119K | Form 4 |
| Mar 31, 2026 | Ryan Savitz | CFO | Sale | 800 | $81.36 | $65.1K | Form 4 |
| Mar 31, 2026 | Ryan Savitz | CFO | Sale | 2,366 | $82.84 | $196K | Form 4 |
| Mar 31, 2026 | Ryan Savitz | CFO | Sale | 59,800 | $83.90 | $5M | Form 4 |
| Mar 31, 2026 | Ryan Savitz | CFO | Sale | 19,469 | $84.57 | $1.6M | Form 4 |
| Mar 31, 2026 | Ryan Savitz | CFO | Sale | 7,232 | $85.54 | $619K | Form 4 |
| Mar 31, 2026 | Ryan Savitz | CFO | Sale | 1,390 | $78.33 | $109K | Form 4 |
| Mar 31, 2026 | Paula Soteropoulos | Director | Sale | 599 | $80.11 | $48K | Form 4 |
| Mar 24, 2026 | Paula Soteropoulos | Director | Sale | 27,594 | $78.05 | $2.2M | Form 4 |
| Mar 12, 2026 | Marino Garcia | CEO | Sale | 65,517 | $81.74 | $5.4M | Form 4 |
| Mar 12, 2026 | Marino Garcia | CEO | Sale | 43,505 | $80.69 | $3.5M | Form 4 |
| Mar 12, 2026 | Marino Garcia | CEO | Sale | 12,796 | $82.60 | $1.1M | Form 4 |
| Mar 12, 2026 | Marino Garcia | CEO | Sale | 200 | $83.38 | $16.7K | Form 4 |
| Mar 12, 2026 | Marino Garcia | CEO | Sale | 900 | $85.53 | $77K | Form 4 |
| Mar 12, 2026 | Edward Carr | CHIEF ACCOUNTING OFFICER | Sale | 15,852 | $80.71 | $1.3M | Form 4 |
| Mar 12, 2026 | Edward Carr | CHIEF ACCOUNTING OFFICER | Sale | 300 | $85.53 | $25.7K | Form 4 |
| Mar 12, 2026 | Edward Carr | CHIEF ACCOUNTING OFFICER | Sale | 3,865 | $82.66 | $319K | Form 4 |
| Mar 12, 2026 | Edward Carr | CHIEF ACCOUNTING OFFICER | Sale | 23,465 | $81.75 | $1.9M | Form 4 |
| Mar 12, 2026 | Simrat Randhawa | Vice president | Sale | 33,830 | $81.48 | $2.8M | Form 4 |
| Dec 4, 2025 | Ryan Savitz | CFO | Sale | 20,000 | $45.18 | $904K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Marino Garcia | CEO AND PRESIDENT, Director | – | $28M | Aug 7, 2026 |
| Ryan Savitz | CFO & CBO | – | $25.5M | Nov 12, 2026 |
| Simrat Randhawa | EVP, Head of R&D | – | $7.6M | Sep 1, 2026 |
| Edward Carr | CHIEF ACCOUNTING OFFICER | – | $5.6M | Sep 17, 2026 |
| Adam M Veness | SVP, General Counsel and Sec. | – | $4.6M | Aug 10, 2026 |
| Paula Soteropoulos | Director | – | $2.3M | May 8, 2026 |
| Anne McGeorge | Director | – | $845K | Aug 10, 2026 |
| Simon Read | Director | – | $631K | Aug 19, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
DNTH short interest
High short interest. 16.6% of DNTH shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 44%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 9.28M DNTH shares were sold short, 16.6% of the shares outstanding, up 3.2% from the report before. At the average daily volume of 914,517 shares, buying them all back would take about 10.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 9.28M | 16.59% | +3% | 914,517 | 10.1 |
| Oct 15, 2026 | 8.99M | 16.07% | -2% | 883,432 | 10.2 |
| Sep 30, 2026 | 9.14M | 16.34% | +4% | 1.10M | 8.3 |
| Sep 15, 2026 | 8.83M | 15.79% | +5% | 612,119 | 14.4 |
| Aug 31, 2026 | 8.43M | 15.07% | +0% | 550,760 | 15.3 |
| Aug 14, 2026 | 8.42M | 15.05% | +0% | 729,436 | 11.5 |
| Jul 31, 2026 | 8.38M | 18.84% | -9% | 882,872 | 9.5 |
| Jul 15, 2026 | 9.22M | 20.73% | -3% | 1.04M | 8.9 |
| Jun 30, 2026 | 9.53M | 21.44% | +37% | 1.74M | 5.5 |
| Jun 15, 2026 | 6.98M | 15.69% | +4% | 1.23M | 5.7 |
| May 29, 2026 | 6.69M | 15.04% | +4% | 615,010 | 10.9 |
| May 15, 2026 | 6.43M | 14.46% | -2% | 450,635 | 14.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Dianthus Therapeutics company events
Dianthus Therapeutics filed 9 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Aug 4, 2026ResultsReleased financial results. Filing
- Jun 12, 2026AnnouncementDianthus Therapeutics, Inc. posted an updated corporate presentation on the investor relations section of its website, which included the following interim responder analysis data for the first 40 patients that completed Part A of the Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory… Filing
- May 22, 2026VoteReported shareholder vote results. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Mar 26, 2026AnnouncementDianthus Therapeutics, Inc. posted an updated corporate presentation on the investor relations section of its website. Filing
- Mar 12, 2026AgreementDianthus Therapeutics, Inc. entered into an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC, Evercore Group L.L.C., Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the underwriters named therein, to issue and sell 7,313,582… Filing
- Mar 9, 2026AnnouncementThe Company made publicly available a data presentation announcing early GO decision following interim responder analysis in Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy on the investor relations section of its website. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Dianthus Therapeutics financials
Famous investors that hold DNTH
5 of the 50 well-known investors we track reported holding DNTH in their latest 13F filing. The largest position is Ken Griffin's, worth $55.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 629,225 | $55.4M | 0.0% | -35% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 290,622 | $25.6M | 0.0% | New |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 272,863 | $24M | 0.0% | +1068% |
| Israel Englander · Millennium Management | Q3 2026 | 211,586 | $18.6M | 0.0% | +130% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 93,353 | $8.2M | 0.0% | +150% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named DNTH in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 10.5% |
| Nov 16, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 10.5% |
| Oct 30, 2026 | Vanguard Capital Management | 13G | 5.1% |
| Oct 30, 2026 | Vanguard Capital Management | 13G | 5.1% |
Questions about Dianthus Therapeutics, Inc. /DE/ (DNTH) stock
Who owns the most DNTH stock?
The largest reported owner of Dianthus Therapeutics, Inc. /DE/ (DNTH) is FMR LLC (Fidelity), with 18.4% of the company. In total, 265 funds and institutions reported holding DNTH at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are DNTH insiders buying or selling?
In the last 12 months, DNTH insiders reported no open-market purchases and 70 sales worth $75M. The latest trade was on Nov 12, 2026. See every trade.
What is the short interest in DNTH?
As of Oct 30, 2026, 9.28M DNTH shares were sold short, 16.6% of the shares outstanding, up 3.2% from the report before. At the average daily volume of 914,517 shares, buying them all back would take about 10.1 trading days (days to cover). See the history.
Which famous investors hold DNTH?
5 of the 50 well-known investors we track reported DNTH in their latest 13F filing, including Ken Griffin, Steve Cohen, Ken Fisher. The largest position is worth $55.4M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.